Inoue M, Inoue Y, Hiramatsu K, Ueda G
Cancer. 1985 Jun 1;55(11):2618-23. doi: 10.1002/1097-0142(19850601)55:11<2618::aid-cncr2820551114>3.0.co;2-s.
Tissue polypeptide antigen (TPA) was measured by radioimmunoassay in sera from patients with various gynecologic tumors: 64 uterine myomas, 129 cervical cancers, 31 endometrial cancers, and 173 ovarian tumors (89 benign, 18 low-grade malignant (LGM) and 66 malignant tumors). Among the cervical cancer patients, the incidence of elevated TPA levels increased with stage of disease from 12% in the preinvasive stage to 67% in the advanced stage. Similarly, the TPA values were elevated in 35% of the endometrial cancer patients. Among the patients with ovarian malignancies, serum TPA was elevated in the following order: LGM cases (33%), Stage I (44%), and advanced (88%). Serum TPA values varied directly with the stage and malignancy of disease, and also correlated with the effect of treatment. However, serum TPA was elevated in 22% of the patients with uterine myoma and in 12% of those with ovarian benign tumors. The current observations demonstrate that the lack of tumor specificity of TPA limits its diagnostic value in gynecologic malignancies, but that serial measurements of this antigen appear to be useful for the evaluation of therapy and monitoring of patients.
采用放射免疫分析法测定了患有各种妇科肿瘤患者血清中的组织多肽抗原（TPA）：64例子宫肌瘤患者、129例宫颈癌患者、31例子宫内膜癌患者以及173例卵巢肿瘤患者（89例良性、18例低级别恶性（LGM）和66例恶性肿瘤）。在宫颈癌患者中，TPA水平升高的发生率随疾病分期增加，从浸润前期的12%增至晚期的67%。同样，35%的子宫内膜癌患者TPA值升高。在卵巢恶性肿瘤患者中，血清TPA升高的顺序如下：LGM病例（33%）、I期（44%）和晚期（88%）。血清TPA值与疾病的分期和恶性程度直接相关，也与治疗效果相关。然而，22%的子宫肌瘤患者和12%的卵巢良性肿瘤患者血清TPA升高。目前的观察结果表明，TPA缺乏肿瘤特异性限制了其在妇科恶性肿瘤中的诊断价值，但对该抗原进行系列测定似乎有助于评估治疗效果和监测患者。
